Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$485.99 USD
+4.10 (0.85%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $486.28 +0.29 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRTX 485.99 +4.10(0.85%)
Will VRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Other News for VRTX
IN BRIEF: Vertex US application for cystic fibrosis treatment accepted
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Vertex to Announce Second Quarter 2024 Financial Results on August 1
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls